News

~

by on

More in News:

The first human trial for the vaccination of the Coronavirus took place in Wuhan, China, and showed a rapid immune response among its one hundred and eight participants

PHOTO CREDITS: THE SCIENTIST

According to Study Finds, a research-based company keeping up with the coronavirus vaccination process, the first human trial for the vaccination of the Coronavirus took place in Wuhan, China, and showed a rapid immune response among its one hundred and eight participants. The vaccination, called adenovirus type 5 vectored COVID-19 (Ad5-nCoV), was given to three groups of thirty-six participants ranging in age from eighteen to sixty. Ad5-nCoV was created from a small dose of the common cold (adenovirus) and was given to the test groups in varying intensities of low, medium, and high. Each group showed a greater level of Coronavirus antibodies than previously experienced and little side effects. Side effects lasted less than two days and included mild pain in the injection area, fever, and fatigue. ~

“These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation,” says Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, who is responsible for the study (Science Daily). The trial showed very promising immunity to COVID-19 in just twenty-eight days; the trial will end in about six months. ~

Although the results of the trial thus far seem to be very promising, there are a few roadblocks to this vaccination. Due to the vaccination being created from the common cold, some of the participants were already immune to it which made the vaccination not as effective or took longer to take effect. “Our study found that pre-existing Ad5 immunity could slow down the rapid immune responses to SARS-CoV-2 and also lower the peaking level of the responses,” said Professor Feng-Cai Zhu from Jiangsu Provincial Center for Disease Control and Prevention (Study Finds). Chen also explains that these findings do not necessarily prove immunity to COVID-19 with the vaccination and that more tests need to be done in order to further develop the vaccine. Another test is underway in China involving adults of all ages, including those over sixty. ~ 

Leave a Reply